{"id":57990,"date":"2023-09-02T01:04:32","date_gmt":"2023-09-01T23:04:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/"},"modified":"2023-09-02T01:04:32","modified_gmt":"2023-09-01T23:04:32","slug":"cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/","title":{"rendered":"Cutera Reports Inducement Grants as permitted by the Nasdaq Listing Rules"},"content":{"rendered":"
\n

BRISBANE, Calif.–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR) (\u201cCutera\u201d or the \u201cCompany\u201d), a leading provider of aesthetic and dermatology solutions, today announced that on August 17,2023 the Compensation Committee of Cutera\u2019s Board of Directors approved the grant of inducement awards to Jeffrey Jones, who joined Cutera on August 28, 2023, as the Chief Operating Officer. The inducement awards consisted of stock options to purchase 31,256 of common stock, restricted stock units (RSUs) settleable in 12,306 shares of common stock, and performance stock units (PSUs) settleable in 24,612 shares of common stock.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe stock options were granted on August 28, 2023, and have an exercise price of $9.61 per share, which is equal to the closing price of a share of Cutera common stock on the grant date. A quantity of 25% shall vest on August 28, 2024, and 1\/48 of the RSUs shall vest each month thereafter, subject to Mr. Jones continuing as an employee.<\/p>\n

\nThe RSUs were granted on August 28, 2023. A quantity of 25% shall vest on August 28, 2024, and 1\/12 of the RSUs shall vest each quarter thereafter, subject to Mr. Jones continuing as an employee.<\/p>\n

\nThe PSUs were granted on August 28, 2023. The performance-based vesting schedule and targets will be determined by Cutera\u2019s Board of Directors or Compensation Committee.<\/p>\n

\nEach inducement award is subject to the terms of the Cutera, Inc. 2023 Inducement Equity Incentive Plan and related forms of agreements and were granted as inducements material to these employees to enter into employment with Cutera in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n

\nAbout Cutera, Inc.<\/b><\/p>\n

\nBrisbane, California-based Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that harness the power of science and nature to enable medical practitioners to offer safe and effective treatments to their patients. For more information, call +1-415-657-5500 or 1-888-4CUTERA or visit www.cutera.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nGreg Barker
\n
VP, Corporate FP&A and Investor Relations
\n
415-657-5500
\n
IR@cutera.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BRISBANE, Calif.–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR) (\u201cCutera\u201d or the \u201cCompany\u201d), a leading provider of aesthetic and dermatology solutions, today announced that on August 17,2023 the Compensation Committee of Cutera\u2019s Board of Directors approved the grant of inducement awards to Jeffrey Jones, who joined Cutera on August 28, 2023, as the Chief Operating Officer. The inducement … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-57990","6":"format-standard","7":"category-industry"},"yoast_head":"\nCutera Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cutera Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BRISBANE, Calif.–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR) (\u201cCutera\u201d or the \u201cCompany\u201d), a leading provider of aesthetic and dermatology solutions, today announced that on August 17,2023 the Compensation Committee of Cutera\u2019s Board of Directors approved the grant of inducement awards to Jeffrey Jones, who joined Cutera on August 28, 2023, as the Chief Operating Officer. The inducement ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-01T23:04:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230901645993\/en\/1880477\/21\/Cutera_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cutera Reports Inducement Grants as permitted by the Nasdaq Listing Rules\",\"datePublished\":\"2023-09-01T23:04:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\\\/\"},\"wordCount\":331,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230901645993\\\/en\\\/1880477\\\/21\\\/Cutera_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\\\/\",\"name\":\"Cutera Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230901645993\\\/en\\\/1880477\\\/21\\\/Cutera_Logo.jpg\",\"datePublished\":\"2023-09-01T23:04:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230901645993\\\/en\\\/1880477\\\/21\\\/Cutera_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230901645993\\\/en\\\/1880477\\\/21\\\/Cutera_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cutera Reports Inducement Grants as permitted by the Nasdaq Listing Rules\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cutera Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/","og_locale":"en_US","og_type":"article","og_title":"Cutera Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Pharma Trend","og_description":"BRISBANE, Calif.–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR) (\u201cCutera\u201d or the \u201cCompany\u201d), a leading provider of aesthetic and dermatology solutions, today announced that on August 17,2023 the Compensation Committee of Cutera\u2019s Board of Directors approved the grant of inducement awards to Jeffrey Jones, who joined Cutera on August 28, 2023, as the Chief Operating Officer. The inducement ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/","og_site_name":"Pharma Trend","article_published_time":"2023-09-01T23:04:32+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230901645993\/en\/1880477\/21\/Cutera_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cutera Reports Inducement Grants as permitted by the Nasdaq Listing Rules","datePublished":"2023-09-01T23:04:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/"},"wordCount":331,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230901645993\/en\/1880477\/21\/Cutera_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/","url":"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/","name":"Cutera Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230901645993\/en\/1880477\/21\/Cutera_Logo.jpg","datePublished":"2023-09-01T23:04:32+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230901645993\/en\/1880477\/21\/Cutera_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230901645993\/en\/1880477\/21\/Cutera_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cutera-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cutera Reports Inducement Grants as permitted by the Nasdaq Listing Rules"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=57990"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57990\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=57990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=57990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=57990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}